Trial reportCell reports. Medicine2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.
Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04398056 (Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab for the de Novo Metastatic Nasopharyngeal Carcinoma), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab for the de Novo Metastatic Nasopharyngeal Carcinoma: a Single Center, Phase II Clinical Trial.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Efficacy and safety of toripalimab in the treatment of nasopharyngeal carcinoma: a meta-analysis of single-arm trials.BMC immunology · 2025Pooled it
- A Telemedicine App for Nonrigid Facial Rehabilitation Training Enhanced by Efficient Fully Convolutional Neural Network With Residual Network (EffiFCNN-ResNet) to Improve Accessibility for Patients With Nasopharyngeal Carcinoma Cancer: Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma.Cell reports. Medicine · 2025Trial
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- ATP-fueled STING activation of manganese coordinated nanoagonist to boost antitumor immunity.Bioactive materials · 2026Article
- Strategies and challenges of toxicity reduction in nasopharyngeal carcinoma in the era of precision radiotherapy: from paradigm shift to integrated decision-making.Frontiers in oncology · 2026Review
- Influence of blood EBV-DNA level on survival of patients with nasopharyngeal cancer on immune checkpoint inhibitors: a meta-analysis.Infectious agents and cancer · 2025Article
- Article
- Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients.Biomedical engineering online · 2025Article
- Efficacy of radiotherapy in treating local recurrence concomitant with distant metastasis of nasopharyngeal carcinoma: a long-term retrospective multicenter study.Clinical & experimental metastasis · 2025Article
- PD-1 inhibitor combined with TPF induction chemotherapy in locally advanced nasopharyngeal carcinoma: a retrospective study of efficacy and safety.Frontiers in immunology · 2025Article
- Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma.Therapeutics and clinical risk management · 2025Article
- The role of immunochemotherapy maintenance in metastatic nasopharyngeal carcinoma: insights from a cohort study in an endemic region.Clinical & translational immunology · 2025Article
- Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023.Biomedicines · 2024Review
- Immunotherapy combined with chemotherapy without locoregional radiotherapy inFrontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 1 country.
Si-Yuan ChenDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Xiao-Tong DuanDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Hui-Feng LiDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Lan PengDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Zhi-Qiang WangDepartment of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China.
Gui-Qiong XuDepartment of Head and Neck Carcinoma and Radiotherapy, Zhongshan City People's Hospital, Zhongshan 528400, Guangdong, China.
Yi-Jun HuaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Xiong ZouDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Rui YouDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Yan-Feng OuyangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
You-Ping LiuDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; Nasopharyngeal Cancer Center, NanChang Hospital, Sun Yat-sen University (The First Hospital of Nanchang), Nanchang 330000, Jiangxi, China.
Chen-Mei GuDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Qi YangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Rou JiangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Meng-Xia ZhangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Mei LinDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Yu-Long XieDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Chao LinDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Xi DingDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Ruo-Qi XieDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Chong-Yang DuanDepartment of Biostatistics, School of Public Health, Southern Medical University, Guangzhou 510000, Guangdong, China.
Wei-Jing ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Pei-Yu HuangDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China.
Ming-Yuan ChenDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510000, Guangdong, China; Nasopharyngeal Cancer Center, NanChang Hospital, Sun Yat-sen University (The First Hospital of Nanchang), Nanchang 330000, Jiangxi, China. Electronic address: chenmy@sysucc.org.cn.
Sun Yat-sen University · CNNanchang University · CNKunming Medical University · CNSouthern Medical University · CNZhongshan People's Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locoregional radiotherapy added to chemotherapy has significantly improved survival in de novo metastatic nasopharyngeal carcinoma (mNPC). However, only 54% of de novo mNPC patients who received sequential chemoradiotherapy have complete or partial response 3 months after radiotherapy. This Simon's optimal two-stage design phase II study (NCT04398056) investigates whether PD-1 inhibitor could improve tumor control in combination with chemoradiation. The primary endpoint is objective response rate (ORR) at 3 months after radiotherapy. Twenty-two patients with primary mNPC are enrolled. The ORR at 3 months after radiotherapy is 81.8% (22.7% complete response, n = 5; 59.1% partial response, n = 13), and the disease control rate is 81.8%. The 3-year progression-free survival (PFS) rate is 44.9% (95% confidence interval 26.4%-76.3%). Fifteen patients (68.2%) experienced grade 3-4 adverse events. Patients with high baseline plasma Epstein-Barr virus DNA copy number (>10
Indexed as
Epstein-Barr Virus InfectionsNasopharyngeal NeoplasmsAntibodies, Monoclonal, HumanizedChemoradiotherapyHerpesvirus 4, HumanHumansNasopharyngeal CarcinomaAntibodies, Monoclonal, Humanizedtoripalimabcombination modality therapyimmune checkpoint inhibitorsmetastasesnasopharyngeal carcinomaPD-1 inhibitortoripalimab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04398056ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.